Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8081872 | 1.00 | CTSK (0.42) | CTSKCTSSCYP3A4KMT2AAAK1 | |
| SCHEMBL8243454 | 1.00 | CTSK (0.42) | CTSKCTSSCYP3A4KMT2AAAK1 | |
| SCHEMBL26125909 | 1.00 | CTSK (0.42) | CTSKCTSSCYP3A4KMT2AAAK1 | |
| SCHEMBL8234220 | 0.96 | CTSK (0.44) | CTSKCTSSCYP3A4KMT2AAAK1 | |
| SCHEMBL8215873 | 0.89 | CTSK (0.41) | CTSKCTSSCYP3A4KMT2AAAK1 | |
| SCHEMBL8245182 | 0.89 | CTSK (0.41) | CTSKCTSSCYP3A4KMT2AAAK1 | |
| SCHEMBL8197090 | 0.88 | CTSK (0.41) | CTSKCTSSCYP3A4KMT2AAAK1 | |
| SCHEMBL30699321 | 0.87 | CTSK (0.41) | CTSKCTSSKMT2ACA1CA2 | |
| SCHEMBL3616266 | 0.86 | CTSK (0.44) | CTSKCTSSCYP3A4KMT2AAAK1 | |
| SCHEMBL3616089 | 0.86 | CTSK (0.44) | CTSKCTSSCYP3A4KMT2AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8198453-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | VITAE PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090318501-A1 | Piperidine derivatives as renin inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090312369-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS , INC. | 2009-12-17 | — | — | US | disclosed |
| WO-2008036247-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | CTSK 152/4885CTSS 95/4885CYP3A4 2510/4885 |
| US-20100184805-A1 | RENIN INHIBITORS | ACE, REN, ACE2 | CTSK 101/4885CTSS 64/4885CYP3A4 1357/4885 |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | ACE, PEPD, DNPEP | CTSK 94/4885CTSS 76/4885CYP3A4 2584/4885 |
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | CTSK 71/4885CTSS 56/4885CYP3A4 3133/4885 |
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | REN, ACE, AGTR1 | CTSK 61/4885CTSS 54/4885CYP3A4 2443/4885 |
| US-20090312369-A1 | Renin Inhibitors | ACE, REN, DNPEP | CTSK 104/4885CTSS 80/4885CYP3A4 1899/4885 |
| US-20090318501-A1 | Piperidine derivatives as renin inhibitors | ACE, DNPEP, PEPD | CTSK 104/4885CTSS 77/4885CYP3A4 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.